

# DRO

Deakin University's Research Repository

Hockings, C., Anwari, K., Ninnis, R. L., Brouwer, J., O'Hely, M., Evangelista, M., Hinds, M. G., Czabotar, P. E., Lee, E. F., Fairlie, W. D., Dewson, G. and Kluck, R. M. 2015, Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax, *Cell death and disease*, vol. 6, pp. 1-8.

DOI: [10.1038/cddis.2015.105](https://doi.org/10.1038/cddis.2015.105)

**This is the published version.**

©2015, Macmillan Publishers

Reproduced by Deakin University under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/)

**Available from Deakin Research Online:**

<http://hdl.handle.net/10536/DRO/DU:30080429>

# Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak *versus* Bax

C Hockings<sup>1,2</sup>, K Anwari<sup>1,2</sup>, RL Ninnis<sup>1,2</sup>, J Brouwer<sup>1,2</sup>, M O'Hely<sup>1,2</sup>, M Evangelista<sup>1,2</sup>, MG Hinds<sup>3,4</sup>, PE Czabotar<sup>1,2</sup>, EF Lee<sup>1,2</sup>, WD Fairlie<sup>1,2</sup>, G Dewson<sup>1,2</sup> and RM Kluck<sup>\*,1,2</sup>

The mitochondrial pathway of apoptosis is initiated by Bcl-2 homology region 3 (BH3)-only members of the Bcl-2 protein family. On upregulation or activation, certain BH3-only proteins can directly bind and activate Bak and Bax to induce conformation change, oligomerization and pore formation in mitochondria. BH3-only proteins, with the exception of Bid, are intrinsically disordered and therefore, functional studies often utilize peptides based on just their BH3 domains. However, these reagents do not possess the hydrophobic membrane targeting domains found on the native BH3-only molecule. To generate each BH3-only protein as a recombinant protein that could efficiently target mitochondria, we developed recombinant Bid chimeras in which the BH3 domain was replaced with that of other BH3-only proteins (Bim, Puma, Noxa, Bad, Bmf, Bik and Hrk). The chimeras were stable following purification, and each immunoprecipitated with full-length Bcl-x<sub>L</sub> according to the specificity reported for the related BH3 peptide. When tested for activation of Bak and Bax in mitochondrial permeabilization assays, Bid chimeras were ~1000-fold more effective than the related BH3 peptides. BH3 sequences from Bid and Bim were the strongest activators, followed by Puma, Hrk, Bmf and Bik, while Bad and Noxa were not activators. Notably, chimeras and peptides showed no apparent preference for activating Bak or Bax. In addition, within the BH3 domain, the h0 position recently found to be important for Bax activation, was important also for Bak activation. Together, our data with full-length proteins indicate that most BH3-only proteins can directly activate both Bak and Bax. *Cell Death and Disease* (2015) 6, e1735; doi:10.1038/cddis.2015.105; published online 23 April 2015

The Bcl-2 family of proteins controls the mitochondrial pathway of apoptosis, a process often dysregulated in cancer and other diseases.<sup>1–3</sup> Apoptotic triggers including DNA damage and oncogene activation cause the synthesis or activation of one or more pro-apoptotic Bcl-2 homology region 3 (BH3)-only proteins,<sup>1–4</sup> a subfamily that includes Bid, Bim, Puma, Noxa, Bad, Bik, Bmf and Hrk. These proteins then engage via their BH3 domain with other Bcl-2 family members. BH3-only proteins that can directly bind and activate the Bcl-2 effector proteins Bak or Bax are called 'activators'.<sup>5</sup> When Bak or Bax become activated and oligomerize in the mitochondrial outer membrane (MOM), the apoptotic 'switch' has flipped and the cell is committed to cell death. The prosurvival members (Bcl-2, Bcl-x<sub>L</sub>, Mcl-1, Bcl-w, Bfl-1/A1 and Bcl-B) inhibit apoptosis by specifically binding both the BH3-only proteins and activated Bak and Bax.<sup>6–11</sup> Thus, the cell's complement of prosurvival proteins, Bak, and Bax, determines the sensitivity of that cell to each BH3-only protein, and by extension to each type of pro-apoptotic stimulus.

A thorough understanding of BH3-only proteins is crucial for the development of cancer therapeutics such as the new class of anti-cancer molecules called BH3 mimetics that are

showing significant promise in clinical trials.<sup>12,13</sup> The binding of BH3-only proteins to prosurvival proteins has been well-characterized and revealed significant preferences for engaging different members.<sup>6,8,9</sup> How BH3-only proteins bind and activate Bak and Bax remains less understood for several reasons. First, generating stable recombinant BH3-only proteins is difficult because, except for Bid, they are intrinsically disordered<sup>14–16</sup> and because most contain hydrophobic C-terminal membrane anchors.<sup>17</sup> Thus, most *in vitro* studies of BH3-only proteins have used synthetic peptides corresponding to the BH3 domains, C-terminally truncated recombinant proteins or *in vitro* translated (IVT) proteins. Second, BH3-only reagents bind poorly to recombinant Bak and Bax in the absence of membranes, although detergents and liposomes may substitute for the MOM.<sup>18–20</sup> Third, activation of Bak and Bax on mitochondria can be complicated by the presence of other proteins such as prosurvival proteins. Indeed, genetically altering BH3-only protein levels in mice resulted in complex phenotypes due to multiple interactions between family members, precluding firm conclusions as to which BH3-only proteins are direct activators.<sup>18,21,22</sup>

<sup>1</sup>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia; <sup>2</sup>Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia and <sup>3</sup>School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia

\*Corresponding author: RM Kluck, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia. Tel: +61 3 9345 2487; Fax: +61 3 9347 0852; E-mail: kluck@wehi.edu.au

<sup>4</sup>Present address: Department of Chemistry and Physics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia.

**Abbreviations:** BH3, Bcl-2 homology region 3; HA, haemagglutinin; IVT, *in vitro* translated; MLM, mouse liver mitochondria; MOM, mitochondrial outer membrane; SDS, sodium dodecyl sulfate; SPR, surface plasmon resonance; TBS, Tris buffered saline

Received 11.8.14; revised 17.3.15; accepted 17.3.15; Edited by T Kaufmann

Bid and Bim are direct activators according to a variety of approaches,<sup>5,8,9,23,24</sup> and were recently proposed to be specific for Bak and Bax, respectively.<sup>25</sup> Early studies using Noxa BH3 peptides<sup>5,8</sup> and IVT Noxa<sup>9</sup> concluded that Noxa was not an activator. However, in more recent studies a Noxa BH3 peptide<sup>23</sup> and purified recombinant Noxa $\Delta$ C<sup>20</sup> were found to be activators of both Bak and Bax. Puma has also been described as both an activator<sup>26,27</sup> and not an activator.<sup>8,28</sup> Du *et al.*<sup>23</sup> analyzed the full panel of BH3 peptides and classified Bim as a strong activator, Bid, Noxa and Bmf as moderate activators, and Puma, Bik and Hrk as weak activators. The only BH3-only member that has never been described as an activator is Bad.


While BH3 peptides and recombinant truncated BH3-only proteins have been useful for *in vitro* studies, new reagents that target mitochondria may better reflect the behavior of the parent proteins. As Bid is stable as a recombinant protein, we generated chimeras of Bid in which the BH3 domain of Bid was replaced with that of seven other BH3-only proteins. This is a similar approach to the Bim chimeras used for expression in cells<sup>18</sup> and in mice.<sup>29</sup> More recently, truncated Bid (tBid) chimeras containing the BH3 domains of Bim, Bak and Bax as well as those of the prosurvival proteins, have been generated as IVT proteins.<sup>11</sup>

To compare the ability of BH3-only proteins to activate Bak and Bax *in vitro*, we incubated Bid chimeras and BH3 peptides with mitochondria containing either Bak or Bax. We found that the membrane-targeted Bid chimeras were much more potent activators than their related BH3 peptides, and that all BH3 domains except for Bad and Noxa were activators to some extent. We conclude that activation of Bak and Bax may be underestimated by studies using BH3 peptides, and that even BH3-only proteins such as Bik, Bmf and Hrk that are often considered unable to activate Bak or Bax, may act as activators under certain conditions.

## Results

### Bid BH3 chimeras are stable as recombinant proteins.

Bid is the only BH3-only protein that can be readily expressed and purified as a recombinant protein. To generate stable proteins that mimic the behavior of the other BH3-only proteins the BH3 domain of human Bid (residues 81–100) was replaced with the BH3 domains of 7 other human BH3-only proteins to create the Bid<sup>Bim</sup>, Bid<sup>Puma</sup>, Bid<sup>Noxa</sup>, Bid<sup>Bad</sup>, Bid<sup>Bik</sup>, Bid<sup>Bmf</sup> and Bid<sup>Hrk</sup> chimeras (Figure 1a). Bid chimeras containing the BH3 domains of Bak and Bax were also generated to explore Bak and Bax function, and to allow comparison with the tBid<sup>Bax</sup> and Bid<sup>Bak</sup> chimeras reported previously.<sup>11</sup> To simplify purification, the caspase-8 cleavage site in Bid was replaced with a thrombin cleavage site, allowing a combined cleavage/purification step.<sup>30</sup> Thus, all Bid chimeras presented in this study are 'cleaved' Bid (also called n/cBid or p7/p15 Bid). A C-terminal haemagglutinin (HA) tag was added to detect chimeras by immunoblotting, and shown not to affect function (Supplementary Figure 1). The swapped BH3 region was initially 20 residues covering the 4 hydrophobic residues (h1–h4) important for binding to prosurvival proteins<sup>31</sup> and the 2 hydrophobic residues (h0)




**Figure 1** Bid BH3 chimeras are stable recombinant proteins. (a) Sequence of Bid BH3 chimeras. Sequence alignment shows the Bid BH3 domain swapped for that of other Bcl-2 family members. Hydrophobic residues (h1–h4) that are important for binding to prosurvival proteins<sup>31</sup> are highlighted, as are the recently identified h0 residues that are important for binding to Bax.<sup>24</sup> (b) Recombinant Bid BH3 chimeras. Chimeras were cleaved by thrombin during purification to generate N-terminal p7 and C-terminal p15 fragments of Bid.<sup>30</sup> Chimeras were separated by SDS-PAGE and stained for total protein

recently shown to be important for binding to Bax.<sup>24</sup> However, four of the chimeras (those with Bim, Noxa, Bmf and Bak BH3 domains) expressed poorly or aggregated during purification (not shown). This may be due to residues that correspond to I83 in Bid (glutamate from Bim, Noxa and Bmf or methionine from Bak, Supplementary Figure 2a) being poorly tolerated. I83 normally makes contact with four hydrophobic residues in helices 1 and 8 that may stabilize the protein (Supplementary Figure 2b).<sup>32</sup> Accordingly, when the swapped domain was shortened to 16 residues to retain I83, the 4 chimeras were stable (Figure 1b). As expected, the p15 fragments of all Bid chimeras retained the ability to translocate to membranes of mouse liver mitochondria (MLM) (Supplementary Figure 2c).

### Bid BH3 chimeras exhibit specific binding to prosurvival proteins.

To evaluate the Bid BH3 chimeras, they were first tested for binding to the Bcl-x<sub>L</sub> prosurvival protein (Figure 2a and Supplementary Figure 3a). Equimolar chimera and full-length Bcl-x<sub>L</sub> were incubated in the presence of Bak<sup>-/-</sup> MLM, and the immunoprecipitated Bcl-x<sub>L</sub> examined for bound chimera. Each chimera, except for Bid<sup>Noxa</sup>, co-precipitated strongly with Bcl-x<sub>L</sub> (Figure 2a, upper panel), consistent with the binding of human BH3 peptides to Bcl-x<sub>L</sub> $\Delta$ C25 measured by surface plasmon resonance (SPR) (Figure 2a, lower panel).<sup>6,7,10</sup>

**C-terminally truncated prosurvival proteins have altered BH3-binding specificity when tested on mitochondria.** When C-terminally truncated Bcl-x<sub>L</sub> ( $\Delta$ C) was tested for binding to Bid chimeras its specificity was significantly



**Figure 2** Bid BH3 chimeras show specific binding to prosurvival proteins. **(a)** Bid BH3 chimeras show specificity in binding to full-length Bcl-x<sub>L</sub>. Bid BH3 chimeras and full-length Bcl-x<sub>L</sub> were incubated at a 1 : 1 molar ratio in the presence of *Bak*<sup>-/-</sup> MLM before solubilization with 1% digitonin, immunoprecipitation (IP) of Bcl-x<sub>L</sub> and Western blotting for bound chimera (HA tag). **(b)** Bid BH3 chimeras binding to truncated Bcl-x<sub>L</sub>, Mcl-1 and Bcl-2. The chimeras were incubated as in **(a)** with the indicated truncated prosurvival proteins. Blots are representative of three independent experiments (shown in Supplementary Figure 3a). Bottom panels show previously published IC<sub>50</sub> values of the equivalent BH3 peptides for binding to truncated prosurvival proteins as measured by SPR.<sup>6,7,10</sup>

different to full-length Bcl-x<sub>L</sub>, with four chimeras (Bid<sup>Bim</sup>, Bid<sup>Bik</sup>, Bid<sup>Hrk</sup> and Bid<sup>Bax</sup>) showing little co-precipitation (Figure 2b and Supplementary Figure 3a). Chimeras bound to the canonical hydrophobic groove in full-length Bcl-x<sub>L</sub>, rather than a site involving the C terminus, as the BH3 mimetic ABT-737 prevented co-precipitation (Supplementary Figure 3b). Altered binding may be due in part to truncated Bcl-x<sub>L</sub> remaining in the supernatant, whereas full-length Bcl-x<sub>L</sub> (and Bid chimeras) was predominantly membrane associated (Supplementary Figure 3c). Consequently, the hydrophobic groove may adopt a different conformation and therefore binding specificity on membrane insertion.

The chimeras also showed specific binding to truncated Mcl-1 (ΔNΔC) and to truncated Bcl-2 (ΔC) (Figure 2b and Supplementary Figure 3a). While binding was similar to that of BH3 peptides on SPR, there were some exceptions.

For example, Bid<sup>Puma</sup> bound poorly to Mcl-1ΔNΔC and Bid<sup>Bim</sup> bound poorly to Bcl-2ΔC (Figure 2b). Thus, membrane insertion may alter the binding profile of several prosurvival proteins.

In the absence of mitochondria, the chimeras immunoprecipitated only weakly with truncated prosurvival proteins (data not shown), consistent with the requirement of membranes for separation of the Bid p7 and p15 fragments and exposure of the Bid BH3 domain.<sup>33–35</sup> Accordingly, SPR (which is performed in the absence of membranes) also failed to detect binding of the chimeras to Bcl-x<sub>L</sub>ΔC and Mcl-1ΔNΔC even in the presence of octyl glucoside (data not shown), a detergent commonly used to separate the p7 and p15 fragments of Bid.<sup>36</sup>

In summary, binding of the chimeras to full-length Bcl-x<sub>L</sub> (in the presence of mitochondria) reflected the specificity of their cognate BH3 peptide. In addition, the importance of



studying full-length Bcl-2 proteins in their native environments was highlighted by the altered binding specificity of Bid chimeras to truncated prosurvival proteins.

**Most BH3 chimeras and peptides activate Bak and Bax, but with different potencies.** To compare the ability of each chimera or related BH3 peptide to activate Bak, wild-type C57BL/6 MLM were incubated with increasing concentrations of chimera or BH3 peptide and tested for cytochrome *c* release. To test activation of Bax, MLM from *Bak*<sup>-/-</sup> mice were supplemented with recombinant full-length Bax.<sup>37</sup> MLM have been used previously to assess Bak and Bax activation<sup>11,24,38,39</sup> as the remaining Bcl-2 proteins were undetectable except for Bcl-x<sub>L</sub> which was present at low levels (<3 nM).<sup>40</sup> Cytochrome *c* release was used as a measure of Bak or Bax activation as the two events correlated strongly in wild-type MLM (Supplementary Figure 1), and no cytochrome *c* release occurred in *Bak*<sup>-/-</sup> MLM without addition of Bax (data not shown).<sup>5,40,41</sup>

Most Bid chimeras induced dose-dependent activation of Bak (release of cytochrome *c*), allowing estimation of their EC<sub>50</sub> (Figure 3a). Similar experiments performed for Bak activation by BH3 peptides, and for Bax activation by Bid chimeras and peptides, allowed us to compare Bak and Bax activation by both types of reagents (Figure 3b). Bid and Bid<sup>Bim</sup> and the related peptides were strong activators of both Bak and Bax (Figure 3b), consistent with previous reports.<sup>5,9,23</sup> Bid<sup>Puma</sup> chimera and Puma peptide were also activators, in agreement with some<sup>9,23,26,27</sup> but not other reports.<sup>8,28</sup> Bmf, Hrk and Bik reagents were activators, with Bik being the weakest. While Bid<sup>Noxa</sup> could also activate both Bak and Bax, the Noxa peptide had no apparent activator activity. As Bid<sup>Bad</sup> chimera and Bad peptide often failed to completely release cytochrome *c*, the EC<sub>50</sub> was not included in Figure 3b. The Noxa and Bad results are discussed in more detail below. Finally, Bid<sup>Bak</sup> and Bid<sup>Bax</sup> chimeras (and equivalent BH3 domain peptides) could activate both Bak and Bax, as previously reported,<sup>11</sup> and consistent with Bak and Bax being able to auto-activate.<sup>42</sup>

By comparing both Bak and Bax activation by each chimera and BH3 peptide, we could draw several conclusions. First, the Bid chimeras were generally > 1000-fold more potent than their related BH3 peptide in activating Bak. This was attributable to the Bid scaffold targeting all chimeras to the MOM (Supplementary Figure 2c), consistent with targeting a Bid peptide to liposomes making it nearly as potent as the Bid protein in activating Bax.<sup>43</sup> The Bid scaffold may also increase the affinity of the BH3 domain by stabilizing its structure, or by aligning the BH3 domain to the activation site on Bak and Bax. Second, the chimeras are reasonable mimics of their parent BH3-only proteins, as the relative potency of each chimera, with the exception of Noxa, reflected the relative potency of the cognate BH3 peptide (Figure 3b). Third, the relative potencies of the chimeras for activating Bak and Bax were similar, as were the potencies of the peptides (Figure 3b and Supplementary Figure 4). Thus, while BH3-only proteins show specificity for certain prosurvival proteins, they may not for Bak and Bax. In particular, in contrast to a recent report,<sup>25</sup> there was little evidence of Bid preferentially targeting Bak and


Bim preferentially targeting Bax, as Bid<sup>Bim</sup> was approximately fourfold less potent than Bid in activating both Bak and Bax.

**Bad does not directly activate Bak or Bax, but can do so indirectly.** Compared with the other BH3-only reagents, the Bid<sup>Bad</sup> chimera and Bad peptide caused a more graded and often incomplete release of cytochrome *c*, particularly in the Bax experiments (Figure 4 and Supplementary Figure 5). This made EC<sub>50</sub> estimations problematic, and suggested that the Bad-like reagents caused cytochrome *c* release indirectly (also called de-repression). As Noxa peptide, that does not bind to Bcl-x<sub>L</sub>,<sup>6</sup> did not cause any cytochrome *c* release (Figure 3b), it is possible that the Bad-like reagents bind endogenous Bcl-x<sub>L</sub> present on MLM to liberate endogenous activators that then activate Bak or Bax. Variable cytochrome *c* release induced by Bad-like reagents (Supplementary Figure 5) might be explained by variation in the levels of Bcl-x<sub>L</sub> and/or direct activators between mitochondria preparations.

To further test direct activation by the chimeras, they were tested for their ability to activate His-tagged BakΔCT on nickel-chelating liposomes (Figure 5), as described previously.<sup>44</sup> While the dose range (from 1 to 3 nM) was more limited in this assay to avoid non-specific permeabilization, each chimera except for Bid<sup>Bad</sup> was able to activate Bak and permeabilize the liposomes. Moreover, the activation profile matched that for full-length Bak in MLM (Figures 3a and b), indicating that other Bcl-2 family proteins in MLM probably had little impact on cytochrome *c* release by all chimeras except Bid<sup>Bad</sup>.

**Noxa does not directly activate Bak or Bax.** The finding that Bid<sup>Noxa</sup>, but not Noxa peptide, could activate Bak and Bax (Figure 3) prompted us to test a recombinant variant of the Noxa protein (Figure 6a). GST-NoxaΔC contains GST at the N-terminus for increased stability and lacks the C-terminal membrane anchor, similar to a variant of Noxa (S peptide-NoxaΔC) reported to bind and activate BakΔC in liposomes.<sup>20</sup> In the MLM, even very high concentrations (10 μM) of GST-NoxaΔC did not activate Bak or Bax (Figure 6a) despite the Noxa BH3 domain being available for binding to Mcl-1 (Figure 6b).

**The Bid h0 contributes to Bak and Bax activation.** Mutagenesis was then used to examine why the Bid<sup>Noxa</sup> chimera activated Bak and Bax, but Noxa peptide and GST-NoxaΔC did not (Figures 3b and 6a). As noted above, the chimera contains the Bid sequence (QEDIIR) around the h0 region recently found to be important for activating Bax.<sup>24</sup> To test whether the h0 region might also contribute to Bak activation, and account for the activator activity of Bid<sup>Noxa</sup>, we replaced the two h0 residues in Bid<sup>Noxa</sup> with alanine, flanked by residues from Bid (Bid<sup>Noxa</sup>h0AA1) or from Noxa (Bid<sup>Noxa</sup>h0AA2) (Figure 6c). Activation of both Bak and Bax was decreased by ~10-fold (Figure 6d), indicating that h0 residues contribute to activation of Bak as well as Bax. In the reverse approach, we attempted to convert the Noxa peptide to an activator by adding Bid sequence (Figure 6c). Introducing just the two h0 isoleucines of Bid (Noxa h0II peptide) was not sufficient, but introducing seven Bid residues (BidNoxa peptide) to mimic the swap in the Bid<sup>Noxa</sup> chimera



**Figure 3** Bid chimeras and BH3 peptides are similar in their specificity for activating both Bak and Bax. (a) Bid chimeras activate Bak to release cytochrome c. Wild-type MLM were treated with the indicated Bid chimeras and supernatant (sup) and pellet (pel) fractions Western blotted for cytochrome c (top panels). Quantification of cytochrome c release allowed estimation of  $EC_{50}$  (bottom panels). (b) Comparison of Bak and Bax activation by Bid chimeras and BH3 peptides. Wild-type MLM (Bak activation) or  $Bak^{-/-}$  MLM plus 10 nM Bax (Bax activation) were treated with Bid chimeras or BH3 peptide. Cytochrome c release was quantified as in a. The  $EC_{50}$  values from three or four independent experiments are shown, and in each graph the values from one experiment are represented by the same symbol. Note that  $EC_{50}$  values for Bid<sup>Bad</sup> and Bad peptide were not estimated because cytochrome c release was often incomplete (see Figure 4)

now converted the peptide to an activator (Figure 6e). Within those seven Bid residues, the h0 residues were required as their substitution with alanine (BidNoxa h0AA peptide) abrogated Bak activation (Figure 6e). Residues flanking h0 may also promote or hinder activation, as BidNoxa peptide but not Noxa h0II peptide could activate Bak and Bax (Figure 6e) and the Bid<sup>Noxa</sup> h0AA1 and h0AA2 mutant chimeras did not lose all activator function (Figure 6d). Results with the Noxa peptide are consistent with reduced Bak activation by a Bid peptide in which truncation had removed the h0 region.<sup>39</sup> In summary, these experiments show that h0 in both peptide and chimera can contribute to Bak activation, as well as Bax activation.<sup>24</sup>

## Discussion


The Bid chimeras were generally >1000 times more potent than BH3 peptides at directly activating Bax/Bak (Figure 3), as previously shown for Bid protein *versus* Bid BH3 peptide.<sup>8,43</sup> The potency of the chimeras may be largely due to membrane targeting by the Bid scaffold, as targeting a Bid peptide to mitochondria rendered it almost as potent as Bid protein;<sup>43,45</sup> induced helicity of the BH3 domain<sup>46,47</sup> or improved 'presentation' of the BH3 domain to Bak or Bax may also contribute. As all BH3-only proteins (except Bad) contain a C-terminal

mitochondrial targeting domain,<sup>17</sup> they are better represented by the Bid chimeras than by BH3 peptides. In addition, as tBid (the p15 fragment) becomes intrinsically disordered when bound to membranes,<sup>48–51</sup> the final tertiary structures of chimeras and parent BH3-only proteins may be similar. Thus, previous studies with BH3 peptides or truncated BH3-only proteins may have underestimated the ability of the parent BH3-only proteins to activate Bak and Bax, and the Bid chimeras provide an improved means of assessing direct activation.


Our studies indicate that each of the BH3-only proteins, except for Bad and Noxa, have some ability to activate Bak and Bax. Bik, Bmf and Hrk are often considered to be 'sensitizers' that function only by binding and sequestering prosurvival proteins. However, as our data indicate that they may also activate Bak and Bax, both functions may be important, as deduced for Bim *in vivo*.<sup>29</sup>

Our comparison of Bak and Bax showed that both were activated by the same chimeras, and by the same peptides (Figure 3 and Supplementary Figure 4). This is consistent with liposome studies in which Bak $\Delta$ N $\Delta$ C and Bax were activated by the same BH3 peptides.<sup>23</sup> Our findings differ from experiments with permeabilized cells (which may contain prosurvival proteins), where Bak was preferentially activated by Bid, while Bax was preferentially activated by Bim.<sup>25</sup> Our findings are more consistent with their experiments with isolated mitochondria and liposomes where the preference was less apparent.<sup>25</sup> Finally, the lack of specificity of BH3-only proteins for activating Bak *versus* Bax, and a role for h0 in activating both Bak and Bax, suggests similar activation sites on both pore-forming proteins. Accordingly, several structures show BH3 peptides bound to the canonical hydrophobic grooves in Bak and Bax.<sup>24,39,52</sup>

In conclusion, cells have various means of activating Bak and Bax, as most BH3-only proteins can directly activate Bak and Bax, and others (Bad and Noxa) may indirectly activate the two proteins. Direct activation is greatly enhanced by targeting to mitochondria, suggesting that studies relying on C-terminally truncated BH3-only proteins and BH3 peptides underestimate direct activation by their parent BH3-proteins. The Bid chimeras developed in this study are targeted to membranes to better represent the interactions between



**Figure 4** Bad-like reagents often induce only partial cytochrome *c* release. Wild-type MLM or Bak<sup>-/-</sup> MLM plus 10 nM Bax were treated with Bid<sup>Bad</sup> or Bad peptide as in Figure 3 and assessed for cytochrome *c* release. Blots are representative of at least four independent experiments (shown in Supplementary Figure 5)




**Figure 5** Each Bid chimera, except for Bid<sup>Bad</sup>, can activate recombinant Bak to permeabilize liposomes. Nickel-chelating liposomes were treated with 150 nM His-tagged Bak $\Delta$ C and Bid chimeras as indicated and tested for the release of 5(6)-carboxy-fluorescein. Data were normalized by subtracting the signal from untreated liposomes, and then expressed as a percentage of the signal induced by permeabilization with 1% CHAPS. Error bars indicate the S.E.M. of four separate experiments. Statistical significance ('NS' not significant, \*\**P* < 0.01, \*\*\**P* < 0.001) was calculated using non-normalized data and a one-tailed Student's *t*-test

BH3-only proteins and Bak and Bax that require a membrane.<sup>17,33,43</sup> Therefore, they are important new tools for *in vitro* studies of Bcl-2 proteins on liposomes, vesicles or mitochondria.

## Materials and Methods

**Generating recombinant proteins and BH3 peptides.** Chimeras of human Bid in which the BH3 domain (aa 81–100) was swapped with 20 residues (human Puma 132–151, Bad 105–124, Bik 52–71, Hrk 28–47 and Bax 52–71) or 16 residues (Bid 85–100 replaced with human Bim 147–162, Noxa 24–39, Bmf 170–



**Figure 6** Noxa is not a direct activator of Bak or Bax. (a) GST-NoxaΔC does not activate Bak or Bax. Wild-type MLM or *Bak*<sup>-/-</sup> MLM plus 10 nM Bax were treated with the indicated Noxa reagents and tested for cytochrome c release. (b) GST-NoxaΔC binds to Mcl-1. GST-NoxaΔC was incubated with Mcl-1ΔNΔC at a 1 : 1 molar ratio in the presence of *Bak*<sup>-/-</sup> MLM before immunoprecipitation of Mcl-1 and Western blotting for Noxa. (c) Sequences of Bid<sup>Noxa</sup> chimera and Noxa BH3 peptide mutations. (d) Activator function of Bid<sup>Noxa</sup> depends partially on the h0 residues of Bid. The Bid<sup>Noxa</sup> chimera variants were tested for activator function as in a. (e) Noxa peptide conversion to an activator depends on the h0 residues of Bid. The Noxa BH3 peptide variants were tested for activator function as in a. Blots are representative of two or more independent experiments



185 and Bak 73–88) by PCR site-directed mutagenesis. The Bid backbone had a thrombin cleavage site in place of the caspase 8 cleavage site to allow one-step cleavage and purification<sup>30</sup> and was cloned into pGEX-4T2 to add a C-terminal HA tag. Protein was expressed in *Escherichia coli* BL21 (DE3) induced with 1 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG) overnight at 18 °C. Bacteria were lysed in lysis buffer (phosphate buffered saline with 1 mM EDTA, 10  $\mu$ g/ml aprotinin and 10  $\mu$ g/ml leupeptin), with 1 mM dithiothreitol (DTT), 0.5 mM phenylmethanesulfonyl fluoride, 266  $\mu$ g/ml lysozyme and 37  $\mu$ g/ml DNase I with a homogenizer (Emulsiflex, Avestin, Ottawa, ON, Canada). The lysate was centrifuged and filtered, before incubation with glutathione beads (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Washed beads were incubated overnight at 4 °C with thrombin in 50 mM Tris pH 8.0, 150 mM NaCl and 5 mM MgCl<sub>2</sub>. Eluate was further purified by gel filtration (Superdex 75, GE Healthcare Bio-Sciences AB) in Tris buffered saline (TBS; 20 mM Tris pH 8.0 and 150 mM NaCl) with 2 mM DTT. Fractions were aliquoted and stored at –80 °C.

Recombinant full-length human Bcl-x<sub>L</sub> was cloned into PTYB1 vector to produce a fusion of Bcl-x<sub>L</sub> with an intein/chitin binding protein, which can be removed to obtain Bcl-x<sub>L</sub> with vector encoded residues Gly–Ser–Ser at the C terminus. Protein was expressed in ER2566 *E. coli* (New England Biolabs, Ipswich, MA, USA) induced with 0.5 mM IPTG overnight at 18 °C. Bacteria were lysed with a homogenizer in TEN buffer (20 mM Tris pH 8.0, 1 mM EDTA, 500 mM NaCl) with 10 mM MgCl<sub>2</sub>, 25  $\mu$ g/ml DNase I and protease inhibitor cocktail (Roche, Basel, Switzerland). CHAPS (1%, Sigma-Aldrich, St Louis, MO, USA) was incubated with lysate for 30 min prior to centrifugation and filtration. Clarified lysate was passed through a column with chitin resin, which was then washed thoroughly with 0.2% CHAPS in TEN buffer. On-column cleavage of the intein tag was induced with 50 mM DTT for at least 40 h at 4 °C. Bcl-x<sub>L</sub> was eluted and further purified by gel filtration (Superdex 200) in TBS. Fractions were concentrated, aliquots flash frozen with liquid nitrogen and stored at –80 °C. Bak $\Delta$ C22-HexHis was produced by the Bax purification protocol described previously.<sup>24</sup> The expression and purification of human Bax, mouse Mcl-1 $\Delta$ N151 $\Delta$ C23, human Bcl-x<sub>L</sub> $\Delta$ C25 and human Bcl-2 $\Delta$ C22 has been described previously.<sup>6,24</sup>

Human Noxa (residue 1–40) was cloned into pGEX 6P3 vector resulting in a C-terminal GST tag. Protein was expressed in *E. coli* BL21 (DE3) induced with 1 mM IPTG for 3 h at 37 °C. Bacteria were homogenized in TBS-E (TBS with 1 mM EDTA). The lysate was centrifuged and filtered before passing through a GST column. The column was then washed with TBS-E and bound proteins eluted with 10 mM reduced glutathione (in TBS-E) then further purified by gel filtration (Superdex 75) in TBS.

Synthetic peptides based on human BH3 sequences were synthesized by Mimotopes (Notting Hill, VIC, Australia) and purified by reverse-phase HPLC to >90% purity. Full peptide sequences are shown in Supplementary Figure 2. Most peptides have been published previously: Bid (34-mer) in Willis *et al.*<sup>18</sup> Bim, Noxa, Bad and Hrk in Chen *et al.*<sup>6</sup> Bak and Bax in Czabotar *et al.*<sup>24</sup> Noxa mutant peptide sequences are shown in Figure 5c.

**Mitochondrial cytochrome c release.** MLM were prepared from C57BL/6 wild-type or Bak<sup>–/–</sup> mice as described.<sup>53</sup> MLM were diluted to 1 mg/ml in MELB (100 mM KCl, 2.5 mM MgCl<sub>2</sub>, 100 mM sucrose, 20 mM HEPES/KOH pH 7.5, 5 mM DTT) supplemented with protease inhibitor cocktail and 4 mg/ml pepstatin A (Sigma-Aldrich). Recombinant full-length Bax, Bid BH3 chimeras, GST-Noxa $\Delta$ C and BH3 peptides were added as indicated, and samples incubated for 2 h at 37 °C. When chimeras were diluted significantly (e.g., dose–response experiments in Figures 3–5), binding of protein to tubes was minimized by the presence of 1% BSA in diluent (final 0.01 to 0.03% BSA). Similarly, peptides were diluted in 100% DMSO (final 1–3% DMSO on). Supernatant and pellet fractions were separated by centrifugation and analyzed by sodium dodecyl sulfate (SDS)-PAGE and Western blotting for cytochrome c.

**SDS-PAGE and Western blotting.** SDS-PAGE and Western blotting was performed as described.<sup>54</sup> Primary antibodies used were anti-cytochrome c 7H8.2C12 mouse monoclonal (BD Biosciences, San Jose, CA, USA), anti-HA 16B12 mouse monoclonal (Covance, Princeton, NJ, USA) or 3F10 rat monoclonal (Roche), anti-Mcl-1 19C4-15 rat monoclonal (WEHI mAb Facility, Bundoora, VIC, Australia<sup>55</sup>), anti-Bcl-x rabbit polyclonal (BD Biosciences), anti-Bcl-2 Bcl-2-100 mouse monoclonal (WEHI mAb Facility<sup>56</sup>), anti-Noxa 114C307 mouse monoclonal (Novus Biologicals, Littleton, CO, USA) and anti-Bak 4B5 rat monoclonal (WEHI mAb Facility<sup>57</sup>). Secondary antibodies were horseradish peroxidase-conjugated goat anti-mouse, goat anti-rabbit and goat anti-rat (Southern Biotech, Birmingham, AL, USA).

**Quantitation of cytochrome c release and dose–response analysis.** Western blot images were quantitated by densitometry with ImageLab

4.1 software (Bio-Rad, Hercules, CA, USA). Percentage cytochrome c release was determined independently from the supernatant and pellet densitometry (using Excel for Mac, Microsoft, Redmond, WA, USA) as follows. Percentage release in supernatant was calculated as the ratio of each density to the maximum density in the supernatant blot. The same calculation for pellet blots gave the percentage of cytochrome c retained; percent release is then obtained by subtracting from 100%. In cases where the densitometry on the pellet did not drop to zero (i.e., 100% cytochrome c is not released) the supernatant percentages for that case were multiplied by densities of sup/(sup+pellet) for the dose corresponding to maximum cytochrome c release. The two measures of cytochrome c release (from supernatant and pellet) were imported into Prism 6 (Graphpad, La Jolla, CA, USA) and treated as two independent measures. Curves were fitted to the data using 'log(agonist) versus response' non-linear regression. 'Top' and 'Bottom' values were fixed at the average minimum and average maximum, respectively, of all blots in that experiment, and the log(EC<sub>50</sub>) and Hill Slope parameters were unconstrained.

**Immunoprecipitation.** For immunoprecipitation of Bid BH3 chimeras with prosurvival Bcl-2 proteins, 40 nM Bid chimeras were incubated with 40 nM hBcl-x<sub>L</sub>, hBcl-x<sub>L</sub> $\Delta$ C25, mMcl-1 $\Delta$ N151 $\Delta$ C23 or hBcl-2 $\Delta$ C22 in the presence of 1 mg/ml Bak<sup>–/–</sup> MLM. After 1 h at 37 °C, samples were solubilized with 1% digitonin and immunoprecipitated as described<sup>57</sup> using anti-Mcl-1 14C11 rat monoclonal,<sup>58</sup> anti-Bcl-x<sub>L</sub> IC2 rat monoclonal<sup>7</sup> or anti-Bcl-2 Bcl-2-100 mouse monoclonal antibodies and Protein G Sepharose 4 fast flow (GE Healthcare Bio-Sciences AB).

**Liposome permeabilization assay.** Bak-mediated liposome assays were based on previously described methods.<sup>44</sup> Liposomes were prepared by drying lipid mixes (46% phosphatidylcholine, 25% phosphatidylethanolamine, 11% phosphatidylinositol, 10% phosphatidylserine, 8% cardiolipin and 10% 18:1 DGS-NTA(Ni) 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1 carboxypentyl) iminodiacetic acid)succinyl] (nickel salt)) in chloroform and 0.01% butylated hydroxytoluene under N<sub>2</sub>, and then resuspending in liposome buffer (10 mM HEPES pH 7.5 and 135 mM KCl) containing 50 mM 5(6)-carboxy-fluorescein. To remove excess free lipid and collect a uniform size liposome mixture the sample was passed over a polycarbonate membrane filter (diameter 19 mm; pore size 0.1  $\mu$ m). To remove unincorporated dye, the liposomes were passed through a PD10 desalting column. For each assay, liposomes were used at a final concentration of 2.5 mM and the fluorescence of released self-quenching 5(6)-carboxy-fluorescein measured at an excitation wavelength of 485 nm and emission wavelength of 535 nm.

## Conflict of Interest

The authors declare no conflict of interest.

**Acknowledgements.** We thank Jerry Adams for critical reading of the manuscript; Stephanie Fennell, Tobias Kratina and Ahmad Wardak for technical assistance; Adeline Robin and Michael Roy for recombinant proteins; David Huang for ABT-737. The work was supported by grants from the National Health and Medical Research Council of Australia (no. 575559, no. 1016701 and no. 1041936), and the Association for International Cancer Research (no. 10–230), and operational infrastructure grants through the Victorian State Government Operational Infrastructure Support and the Australian Government NHMRC IRIISS.

1. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. *Nat Rev Mol Cell Biol* 2008; **9**: 47–59.
2. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. *Nat Rev Mol Cell Biol* 2014; **15**: 49–63.
3. Shamas-Din A, Kale J, Leber B, Andrews DW. Mechanisms of action of Bcl-2 family proteins. *Cold Spring Harb Perspect Biol* 2013; **5**: a008714.
4. Haplo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. *J Cell Sci* 2012; **125**: 1081–1087.
5. Letai AG, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. *Cancer Cell* 2002; **2**: 183–192.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG *et al.* Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. *Mol Cell* 2005; **17**: 393–403.
7. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI *et al.* Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x<sub>L</sub>, but not Bcl-2, until displaced by BH3-only proteins. *Genes Dev* 2005; **19**: 1294–1305.
8. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR *et al.* BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. *Mol Cell* 2005; **17**: 525–535.

9. Kim H, Rafiuddin-Shah M, Tu H-C, Jeffers JR, Zambetti GP, Hsieh JJ *et al.* Hierarchical regulation of mitochondrial-dependent apoptosis by BCL-2 subfamilies. *Nat Cell Biol* 2006; **8**: 1348–1358.
10. Fletcher JL, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD *et al.* Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. *Proc Natl Acad Sci USA* 2008; **105**: 18081–18087.
11. Llambi F, Moldoveanu T, Tait SWG, Bouchier-Hayes L, Temirov J, McCormick LL *et al.* A unified model of mammalian BCL-2 protein family interactions at the mitochondria. *Mol Cell* 2011; **44**: 517–531.
12. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S *et al.* ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res* 2008; **68**: 3421–3428.
13. Souers AJ, Levenson JD, Boghaert ER, Ackler SL, Catron ND, Chen J *et al.* ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med* 2013; **19**: 202–208.
14. Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DCS *et al.* Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to pro-survival Bcl-2 targets. *Cell Death Differ* 2007; **14**: 128–136.
15. Barrera-Vilarmas S, Obregón P, de Alba E. Intrinsic order and disorder in the bcl-2 member harakiri: insights into its proapoptotic activity. *PLoS One* 2011; **6**: e21413.
16. Peng Z, Xue B, Kurgan L, Uversky VN. Resilience of death: intrinsic disorder in proteins involved in the programmed cell death. *Cell Death Differ* 2013; **20**: 1257–1267.
17. Wilfling F, Weber A, Potthoff S, Vögtle F-N, Meisinger C, Paschen SA *et al.* BH3-only proteins are tail-anchored in the outer mitochondrial membrane and can initiate the activation of Bax. *Cell Death Differ* 2012; **19**: 1328–1336.
18. Willis SN, Fletcher JL, Kaufmann T, van Delft MF, Chen L, Czabotar PE *et al.* Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. *Science* 2007; **315**: 856–859.
19. Billen LP, Kokoski CL, Lovell JF, Leber B, Andrews DW. Bcl-XL inhibits membrane permeabilization by competing with Bax. *PLoS Biol* 2008; **6**: e147.
20. Dai H, Smith A, Meng XW, Schneider PA, Pang YP, Kaufmann SH. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. *J Cell Biol* 2011; **194**: 39–48.
21. Ren D, Tu H-C, Kim H, Wang GX, Bean GR, Takeuchi O *et al.* BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. *Science* 2010; **330**: 1390–1393.
22. Villunger A, Labi V, Bouillet P, Adams JM, Strasser A. Can the analysis of BH3-only protein knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak? *Cell Death Differ* 2011; **18**: 1545–1546.
23. Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. *J Biol Chem* 2011; **286**: 491–501.
24. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD *et al.* Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. *Cell* 2013; **152**: 519–531.
25. Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L *et al.* BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. *Mol Cell* 2013; **51**: 751–765.
26. Cartron P-FF, Gallenne T, Bougras G, Gautier F, Manero F, Vusio P *et al.* The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. *Mol Cell* 2004; **16**: 807–818.
27. Dai H, Pang YP, Ramirez-Alvarado M, Kaufmann SH. Evaluation of the BH3-only protein Puma as a direct Bak activator. *J Biol Chem* 2014; **289**: 89–99.
28. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer SJ, Armstrong SA *et al.* Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. *Cancer Cell* 2006; **9**: 351–365.
29. Merino D, Giam M, Hughes PD, Siggs OM, Heger K, O'Reilly LA *et al.* The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like pro-survival proteins. *J Cell Biol* 2009; **186**: 355–362.
30. Ahsen von O, Renken C, Perkins G, Kluck RM, Bossy-Wetzel E, Newmeyer DD. Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release. *J Cell Biol* 2000; **150**: 1027–1036.
31. Sattler M, Liang H, Nettesheim DG, Meadows RP, Harlan JE, Eberstadt M *et al.* Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. *Science* 1997; **275**: 983–986.
32. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. *Cell* 1999; **96**: 615–624.
33. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B *et al.* Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. *Cell* 2008; **135**: 1074–1084.
34. García-Sáez AJ, Ries J, Orzáez M, Pérez-Payá E, Schwill P. Membrane promotes tBID interaction with BCL(XL). *Nat Struct Mol Biol* 2009; **16**: 1178–1185.
35. Bleicken S, García-Sáez AJ, Conte E, Bordignon E. Dynamic interaction of cBid with detergents, liposomes and mitochondria. *PLoS One* 2012; **7**: e35910.
36. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. *Science* 2000; **290**: 1761–1765.
37. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher JK *et al.* A stapled BID BH3 helix directly binds and activates BAX. *Mol Cell* 2006; **24**: 199–210.
38. Renault TT, Floros KV, Chipuk JE. BAK/BAX activation and cytochrome c release assays using isolated mitochondria. *Methods* 2013; **61**: 146–155.
39. Moldoveanu T, Grace CR, Llambi F, Nourse A, Fitzgerald P, Gehring K *et al.* BID-induced structural changes in BAK promote apoptosis. *Nat Struct Mol Biol* 2013; **20**: 589–597.
40. Uren RT, Dewson G, Chen L, Coyne SC, Huang DCS, Adams JM *et al.* Mitochondrial permeabilization relies on BH3 ligands engaging multiple pro-survival Bcl-2 relatives, not Bak. *J Cell Biol* 2007; **177**: 277–287.
41. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M *et al.* tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. *Genes Dev* 2000; **14**: 2060–2071.
42. Ruffolo SC, Shore GC. BCL-2 selectively interacts with the BID-induced open conformer of BAK, inhibiting BAK auto-oligomerization. *J Biol Chem* 2003; **278**: 25039–25045.
43. Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD, Korsmeyer SJ. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX *in vitro*. *J Biol Chem* 2006; **281**: 36999–37008.
44. Oh KJ, Singh P, Lee K, Foss K, Lee S, Park M *et al.* Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. *J Biol Chem* 2010; **285**: 28924–28937.
45. Terrones O, Etchebarria A, Landajuela A, Landeta O, Antonsson B, Basañez G. BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes. *J Biol Chem* 2008; **283**: 7790–7803.
46. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD *et al.* Activation of apoptosis *in vivo* by a hydrocarbon-stapled BH3 helix. *Science* 2004; **305**: 1466–1470.
47. Rogers JM, Oleinikovas V, Shamas SL, Wong CT, De Sancho D, Baker CM *et al.* Interplay between partner and ligand facilitates the folding and binding of an intrinsically disordered protein. *Proc Natl Acad Sci USA* 2014; **111**: 15420–15425.
48. Gong X-M, Choi J, Franzin CM, Zhai D, Reed JC, Marassi FM. Conformation of membrane-associated proapoptotic tBid. *J Biol Chem* 2004; **279**: 28954–28960.
49. Yao Y, Bobkov AA, Plesniak LA, Marassi FM. Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL. *Biochemistry* 2009; **48**: 8704–8711.
50. Rautureau GJP, Day CL, Hinds MG. Intrinsically disordered proteins in bcl-2 regulated apoptosis. *Int J Mol Sci* 2010; **11**: 1808–1824.
51. Wang Y, Tjandra N. Structural insights of tBid, the caspase-8-activated Bid, and its BH3 domain. *J Biol Chem* 2013; **288**: 35840–35851.
52. Brouwer JM, Westphal D, Dewson G, Robin AY, Uren RT, Bartolo R *et al.* Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. *Mol Cell* 2014; **55**: 938–946.
53. Uren RT, Dewson G, Bonzon C, Lithgow T, Newmeyer DD, Kluck RM. Mitochondrial release of pro-apoptotic proteins: electrostatic interactions can hold cytochrome c but not Smac/DIABLO to mitochondrial membranes. *J Biol Chem* 2005; **280**: 2266–2274.
54. Tran VH, Bartolo R, Westphal D, Alsop A, Dewson G, Kluck RM. Bak apoptotic function is not directly regulated by phosphorylation. *Cell Death Dis* 2013; **4**: e452.
55. Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN *et al.* A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. *J Cell Biol* 2008; **180**: 341–355.
56. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. *Am J Pathol* 1990; **137**: 225–232.
57. Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM *et al.* To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. *Mol Cell* 2008; **30**: 369–380.
58. Banerjee A, Grumont R, Gugasyan R, White C, Strasser A, Gerondakis S. NF-kappaB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms. *Blood* 2008; **112**: 5063–5073.



**Cell Death and Disease** is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>